Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Novartis Pharma AG Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of…
Browsing Tag